CSTLCastle Biosciences, Inc.
Is it safe?
Caution warranted: heavy debt (BB) and big price swings.
Insiders were net sellers (-$516K, 90 days to Oct 8, 2026), selling is often routine.
Net cash, but unprofitable, speculative. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -88% · now 22% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can CSTL take a bad year?
Castle Biosciences, Inc. holds $257M more cash than debt, and is burning $122K a quarter, about 545.6 years of cover.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Cash runway
- 5+ years
Cash runway · burning $122K a quarter at the current rate
- Annualised volatility
- 59%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Total debtQ2 2026
- $10M
- Cash and short-term investments
- $267M
- Net cash
- $257M
- EBITDA, trailing twelve months
- −$21M
- Operating profit, trailing twelve months
- −$32M
- Debt / equity
- 0.02×
- Annualised volatilitytwo years of daily moves
- 59%
- Worst drawdown on file
- −88%
- Below its 52-week high
- 22%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Diagnostics & Research
Ranks #11 of 21 by RyuScore